HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease.

AbstractBACKGROUND:
Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations.
METHODS:
In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302.
RESULTS:
For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day.
CONCLUSIONS:
Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.
AuthorsAndrew Lees, Stanley Fahn, Karla M Eggert, Joseph Jankovic, Anthony Lang, Federico Micheli, M Maral Mouradian, Wolfgang H Oertel, C Warren Olanow, Werner Poewe, Olivier Rascol, Eduardo Tolosa, David Squillacote, Dinesh Kumar
JournalMovement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 27 Issue 2 Pg. 284-8 (Feb 2012) ISSN: 1531-8257 [Electronic] United States
PMID22161845 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Movement Disorder Society.
Chemical References
  • Excitatory Amino Acid Antagonists
  • Nitriles
  • Pyridones
  • perampanel
Topics
  • Aged
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Excitatory Amino Acid Antagonists (therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Nitriles
  • Parkinson Disease (drug therapy)
  • Pyridones (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: